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Abstract
Osteosarcomas are malignant tumors of bone, most commonly seen in children and adoles-
cents. Despite advances in modern medicine, the poor survival rate of metastatic osteosar-
coma has not improved in two decades. In the present study we have investigated the effect
of Riluzole on a human and mouse metastatic osteosarcoma cells. We show that LM7 cells
secrete glutamate in the media and that mGluR5 receptors are required for the proliferation
of LM7 cells. Riluzole, which is known to inhibit glutamate release, inhibits proliferation,
induces apoptosis and prevents migration of LM7 cells. This is also seen with Fenobam, a
specific blocker of mGluR5. We also show that Riluzole alters the phosphorylation status of
AKT/P70 S6 kinase, ERK1/2 and JNK1/2. Thus Riluzole is an effective drug to inhibit prolif-
eration and survival of osteosarcoma cells and has therapeutic potential for the treatment of
osteosarcoma exhibiting autocrine glutamate signaling.
Introduction
Osteosarcoma is the most common malignant primary cancer of bone occurring in young
adults and adolescents [1, 2]. The 5-year survival rate has not improved in the last two decades
[3]. Thus, new therapeutic strategies need to be developed in order to improve the treatment
and survival outcomes in osteosarcoma patients.
Glutamate is a major excitatory neurotransmitter in the human central nervous system,
playing an important role in memory and learning processes. It also plays a key role in cellular
homeostasis and serves as a fuel for metabolic pathways in other tissue types [4, 5]. Recently
the role of glutamate signaling has been discovered in peripheral tissues including bone, play-
ing a vital role in bone survival and differentiation [6–9]. Importantly, some cancers have been
shown to gain growth advantage by exploiting autocrine/paracrine glutamate signaling [10–
12]. Non-neuronal cancers such as breast cancer, melanoma, and prostate cancer [11–15]
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utilize glutamaterigic system for their growth by over expression of glutamate receptors [11,
12]. Furthermore, cancer types such as rhabdomyosarcoma, neuroblastoma, thyroid carci-
noma, lung carcinoma, astrocytoma, multiple myeloma, lung carcinoma, colon adenocarci-
noma, T cell leukemia cells, breast carcinoma, colon adenocarcinoma including brain tumor
cells, also express glutamate receptors suggesting that glutamate might play a role in these can-
cers [16].
There are two types of glutamate receptors, ionotropic and metabotropic receptors.
Ionotropic glutamate receptors are ion channels such as NMDA, AMPA and Kainate recep-
tors. Metabotropic glutamate receptors, mGluR, are G protein coupled receptors and are
categorized into Group I, Group II and Group III receptors depending upon the homology,
agonist selectivity and signal transduction pathways. Both ionotropic and metabotropic glu-
tamate receptors are expressed in the brain and peripheral tissues [17–19]. It is known that
some iontotropic and metabotropic glutamate receptors are aberrantly expressed in several
types of cancers [11, 20]. In this context, exogenous expression of metabotropic glutamate
receptor 1 in immortalized primary baby mouse kidney cells induced tumorigenicity [21].
Although glutamate receptors are normally expressed in brain, several gliomas utilize the
glutamatergic system for the progression of malignancy [22, 23]. Furthermore, triple nega-
tive breast cancer cell lines, which lack estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor (HER2/neu), express metabotropic glutamate
receptor 1, mGluR1. Treatment of such triple negative breast cancer with pharmacological
agents like Riluzole, a glutamate release inhibitor, inhibits cell proliferation [24]. Interest-
ingly, Riluzole has been shown to prevent proliferation of glioblastoma cells, U87, in culture
and in xenograft models [25, 26]. Moreover, Riluzole has been observed to reduce the
growth of cancer cells in culture or in xenograft models for melanoma, breast and prostate
cancers [24, 27, 28]. Riluzole in a clinical trial for melanoma patients proved to be very
promising and showed decreased tumor size or decrease intensity on PET scan in signifi-
cant number of patients that were enrolled in this study [29]. Another study using mela-
noma cell lines and xenograft showed that Riluzole is more effective when used in
combination with mTOR inhibitor [30].
Based on current literature and the therapeutic promise of Riluzole in some cancers, we
have investigated Riluzole as a potential therapeutic agent for osteosarcoma, using LM7 cells.
LM7 cells are human metastatic osteosarcoma cells that show aggressive and invasive growth
behavior [31]. Towards this aim, we have investigated the role of glutamate in survival, prolif-
eration and migration of LM7 cells. Our results demonstrate that Riluzole blocks proliferation,
induces apoptosis and prevents migration of LM7 cells. Furthermore, Riluzole treatment
inhibits glutamate signaling through PI3K/AKT/mTOR and other pathways in LM7 prolifera-
tion. Importantly, knockdown of mGluR5 prevents cell proliferation in LM7 cells. These data
demonstrate the importance of mGluR5 signaling in osteosarcoma growth and provide sup-
port for Riluzole as a potential drug for treating osteosarcoma.
Materials and methods
Cell culture
Human osteosarcoma, LM7 cells [31] and mouse osteosarcoma cells [32, 33] were maintained
in DMEM supplemented with 4.5% glucose, 1mM pyruvate, 2mM glutamate, 10% fetal bovine
serum, 100 units/mL penicillin and 100 μg/mL streptomycin. Cells were passaged every 4 days.
Cells were maintained at 37˚C with 95% air and 5% CO2. When indicated, cells were seeded in
DMEM media without glutamate, penicillin and streptomycin and 0.5% fetal bovine serum.
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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Glutamate assay
Glutamate assay was carried out using a glutamate assay kit from BioVision Incorporated as
per the manufacturer’s instructions. Briefly, 500 cells were seeded in 24 well plates in 1 ml of
media devoid of glutamine and supplemented with 2mM Glutagro to prevent interference
during glutamate assay. On day 0, cells were seeded, the cell viability was determined and the
media was collected for the glutamate assay. Triplicate media samples from independent wells
were collected each day until day 7 and cell viability was performed using Trypan blue assay.
Drug treatments
1.5 X 104 cells were seeded onto polylysine coated coverslips in 24 well plates. Twenty-four
hour later the cells were treated with drugs such as 100 μM Riluzole, or 50 μM DHPG (S)-
3,5-Dihydroxyphenylglycine or 40 μM CPCCOEt ((−)-ethyl (7E)-7-hydroxyimino-1,7a-dihy-
drocyclopropa[b]chromene-1a-carboxylate) or 300 μM Fenobam as specified in each experi-
ment for 72 hours. All drugs were purchased from R&D systems, Minneapolis, MN.
Proliferation assay
Proliferation assays were performed as described by Yelskaya et al [25]. Post drug treatment,
the cells were fixed in 4% paraformaldehyde for 10 min and permeabilized in 0.2% triton X-
100 for 5 min. The cells were washed well with 1X Phosphate buffered saline (PBS) and then
blocked with 10% bovine serum albumin made in 1X PBS. Immunocytochemistry was carried
out using primary antibodies such as polyclonal rabbit anti-Ki-67 (Thermo Fisher Scientific)
followed by Alexa 488-conjugated anti-rabbit secondary antibody. The samples were mounted
in mounting media (Molecular Probes) containing DAPI for nuclear staining. Images were
captured at 20X magnification using a Zeiss fluorescence microscope. The images were used
for counting DAPI positive and Ki-67 positive cells. At least five images were used from each
sample and the experiments were repeated at least four times.
TUNEL assay
The TUNEL assay was performed using the In situ cell death detection kit from Roche as per
manufacturer’s instructions. Briefly, after cells were fixed with 4% paraformaldehyde and per-
meabilized in 0.2% Triton X-100, the TUNEL assay was carried by incubating the fixed cells
with the TUNEL reagent containing TMR red labeled nucleotides at 37˚ C for 1 hour. The
samples were washed in 1X PBS and mounted in mounting media containing DAPI. Fluores-
cent images were captured using a Zeiss fluorescence microscope at 20X magnification. The
total number of DAPI positive cells and total number of TUNEL positive cells were counted
from at least five images from each sample. Each experiment was repeated four times.
Scratch assay
The scratch assay was carried out as described by Goldberg and Kloog [34]. Briefly, 1 million
cells/well were seeded on poly-lysine coated 6-well dishes. After 24 hours media was replaced
with glutamate free low serum media (0.5% FBS) containing drugs. After 24 hours, three
scratches were made and the media was replaced with fresh media containing drugs. Images
were captured at 10X with a phase contrast inverted microscope at 0, 8 and 24 hours. Each
sample had three scratches and the experiment was repeated three times. Gap width was calcu-
lated by taking 150 measurements from each scratch, using SPOT software (SPOT Imaging),
to determine average width. Distance travelled by the cells into the gap was calculated as arbi-
trary units using the width difference in samples at 0, 8 and 24 hours post scratch.
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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Western blotting
Western blotting was carried out using either whole cell extracts solubilzed in 2X SDS loading
buffer or Medium salt extraction buffer (250 mM KCl, 10 mM Tris-HCl [pH 7.9], 5% glycerol,
0.25% NP-40, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium vana-
date, 50 μM sodium fluoride, 1 mM dithiothreitol). Antibodies used were anti total AKT (Cell
Signaling Technology) or rabbit anti Phospho-Akt (Ser473) Antibody (Cell Signaling Technol-
ogy) or rabbit anti phospho T308AKT (Millipore), anti Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (D13.14.4E) XP rabbit mAb (Cell Signaling Technology), anti Phospho-p70
S6 Kinase (Thr389) antibody (Cell Signaling Technology), anti p70 S6 Kinase Antibody (Cell
Signaling Technology), anti p44/42 MAPK (Erk1/2) Antibody (Cell Signaling Technology)
anti Phospho-SAPK/JNK (Thr183/Tyr185) (81E11), rabbit mAb and anti JNK2 (56G8), rabbit
mAb (Cell Signaling Technology). We used Anti-metabotropic Glutamate Receptor 5 Anti-
body (Millipore Sigma) to check expression of mGluR5 and anti mGluR1 (BD Biosciences) for
mGluR1 expression. μ-Tubulin (Thermo Fisher Scientific) was used for loading control. Signal
was detected using chemiluminiscence using Pierce reagents. Western blots were quantified
by measuring the relative densities of the bands using Li-Cor software. The ratio of the phos-
phorylated protein to total protein was calculated and analyzed by Student’s T test.
Knock down of mGluR5 expression in LM7 cells
Metabotropic glutamate receptor 5 expression was knocked down using Lentivirus vector
TRC version 2, pLKO.1-puro vector, expressing ShRNA for mGluR5 (TRCN0000367851-
CCGGTTGTGATCAACGCCATCTATTCTCGAGAATAGATGGCGTTGATCACAATTTTTG). Non-
target ShRNA (SCH002) was used as control. The Lentiviruses for mGluR5 and control were
produced using 293T cells. LM7 cells were infected with various titers of viruses expressing
either ShRNA for mGluR5 or virus containing control ShRNA. Stable cells were selected in
media containing puromycin (1.5 μg/ml). Stable cells containing the control ShRNA or
expressing ShRNA for mGluR were isolated as individual colonies and tested for expression of
mGluR5.
Colonogenic assay
The colonogenic assay was performed as described by Franken et al [35]. Briefly, 500 cells of
mGluR KO or vector control were seeded in puromycin containing media in 6 cm dishes. WT
LM7 cells were seeded in media without puromycin in 6 cm dishes. The cells were incubated
for about 2 weeks until colonies were visible in WT and control. ShRNA The colonies were
fixed in 4% paraformaldehyde and stained with 0.5% Cresyl violet in water. Three independent
experiments were performed and the average number of colonies was obtained.
Statistical analysis
The overall significance was determined by two-way ANOVA using Prism (Graphpad) soft-
ware and significance between each group was determined by pos-hoc analysis using Bornfer-
oni test.
Results
LM7 cells secrete glutamate in the media
To determine whether LM7 cells secrete glutamate in the media we assayed glutamate released
in the media using a colorimetric glutamate assay as described in the Material and Methods.
The results are shown in Fig 1 in which HeLa cells were used as a negative control and show a
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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baseline amount of glutamate in the media. U87, glioblastoma cells, which are known to
secrete high levels of glutamate were used as a positive control and showed increasing amount
of glutamate secretion increasing from 0.18 μ/ml to above 0.94 μ/ml from day 3 to day 7.
Importantly, LM7 cells also secreted glutamate that increased from 0.15 μ/ml to 0.6μ/ml on
day 7. These data show that LM7 cells secrete significant levels of glutamate into the media.
Cell viability for all cell lines was measured throughout the assay period on each day using Try-
pan blue assay (Table 1). The cell viability in all samples remained between 98–99% ensuring
that the measured glutamate was released into the media by living cells and not from dead or
damaged cells. Three independent experiments were performed and the data shown is the
average of all three experiments.
The percentage of viability for each sample in Fig 1 for all cell lines was determined every
day using Trypan Blue. The experiment was repeated three times and the average of three
experiments is shown.
Riluzole inhibits cell proliferation of LM7 and OS482 cells in a dose-
dependent manner
To study the effect of glutamate on growth of osteosarcoma cells, we treated LM7 cells with
Riluzole. We grew LM7 cells in media containing either 0.5% or 10% serum and treated them
with or DMSO as a control or various doses of Riluzole, as indicated. We performed a prolifer-
ation assay as described in Materials and Methods. In the presence of 0.5% serum, Riluzole
decreased the total number of cells, shown by DAPI positive cells, as the dose of Riluzole
increased from 1 μM to 100 μM (Fig 2) (p value<0.001 for 50 μM and 100 μM compared to
control). The number of Ki-67 positive proliferating cells also declined with increasing dose of
Riluzole (p value <0.001 for 50 μM and 100 μM). In control cells, almost 50% of cells prolifer-
ate as indicated by Ki-67 staining (Fig 2A). Interestingly, in the presence of 10% serum, Rilu-
zole at 1 μM slightly increased the total number of cells, indicated by DAPI staining, compared
Fig 1. LM7 cells secrete glutamate. Glutamate secreted by LM7 cells was measured in the media from day
0 to day 7. U87 cells were used a positive control represented by triangles and HeLa cells were used as a
negative control, shown as circles. LM7 cells are shown as squares. The experiment was repeated three
times and the average concentrations are shown.
doi:10.1371/journal.pone.0171256.g001
Table 1. Cell Viability.
Cell Type Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
U87 99.8%+/-0.14 99.7%+/-0.11 99.5%+/-0.10 99.6%+/-0.17 99.6%+/-0.15 99.4%+/-0.17 98.8%+/-0.18
LM7 99.7%+/-0.12 99.7%+/-0.15 99.6%+/-0.12 99.5%+/-0.14 99.6%+/-0.18 99.3%+/-0.18 98.7%+/-0.19
HeLa 99.8%+/-0.07 99.6%+/-0.11 99.7%+/-0.13 99.6%+/-0.16 99.5%+/-0.17 99.4%+/-0.18 98.6%+/-0.20
doi:10.1371/journal.pone.0171256.t001
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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to the control sample. However, the total number of cells declined with higher doses of Riluzole
from 5 μM to 100 μM (p value<0.001 for 50 μM and 100 μM). Riluzole also decreased the
Fig 2. Riluzole inhibits growth of LM7 and OS482 cells both in 0.5% and 10% serum. A. Proliferation of LM7 cells was measured in
the presence of 0.5% serum containing media. Riluzole was added at various concentrations as indicated for 72 hours. The blue bars
represent total number of DAPI positive cells and the green bars represent total number of Ki-67 positive cells (P value <0.001 = ***). B.
Proliferation of LM7 cells was measured in the presence of 10% serum containing media. Riluzole was added at various concentrations
as indicated. The blue bars represent total number of DAPI positive cells and the green bars represent total number of Ki-67 positive
cells (P value <0.001 = ***). C. Representative images of cells from each sample in 10% serum are shown. D. Proliferation of mouse
osteosarcoma cells, OS482, was measured in the presence of 0.5% serum containing media. Riluzole was added at various concentrations
as indicated for 72 hours. The blue bars represent total number of DAPI positive cells and the green bars represent total number of Ki-67
positive cells (P value <0.001 = ***). E. Proliferation of OS482 cells was measured in the presence of 10% serum containing media.
Riluzole was added at various concentrations as indicated. The blue bars represent total number of DAPI positive cells and the green bars
represent total number of Ki-67 positive cells (P value <0.001 = ***).
doi:10.1371/journal.pone.0171256.g002
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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number of proliferating Ki-67 positive cells in a dose dependent manner from 5 μM to 100 μM
(Fig 2B) (p value<0.001 for 50 μM and 100 μM). Representative images in Fig 2C show
decreasing number of DAPI positive and Ki-67 positive cells as the dosage of Riluzole increases
in 10% serum. As expected, in the presence of 10% serum, control samples showed higher num-
ber of proliferating Ki-67 positive cells compared to control sample in 0.5% serum. Furthermore
at 0.5% serum, 10 μM Riluzole decreased cell numbers by 50% while in 10% serum, 68% of cells
remained compared to the control sample. Importantly, at 50 μM and above, Riluzole decreased
total cell numbers to below 20 and 15% in 0.5% and 10% serum, respectively. Similarly, Riluzole
inhibited proliferation of mouse osteosarcoma cells, OS482 cells, in a dose dependent manner
in 0.5% serum and 10% serum (Fig 2D and 2E) (p value<0.001 for 50 μM and 100 μM). As
observed with LM7 cells, OS482 cells showed higher proliferation in 10% serum compared to
0.5% serum (Fig 2D and 2E). Therefore we have utilized Riluzole at 50 μM to treat LM7 and
OS482 cells growing in 10% serum containing media for rest of the experiments unless speci-
fied. The results in these experiments demonstrate that Riluzole decreases both total numbers
of DAPI positive cells and proliferating LM7 cells and OS482 cells. Interestingly, the percentage
of proliferating cells in each sample at any given dosage was similar to that of control, which
was calculated based on the number of DAPI cells in each sample. The % of proliferation was
between 79 to 82 compared to the DAPI cells in 10% serum and did not decrease with the
increase in the dosage of Riluzole. This suggested that the proportion of proliferating cells in
each sample was same irrespective of the drug treatment or dosage of the drug.
Riluzole induces apoptosis in LM7 and OS482 cells
Our data indicate that treatment with Riluzole decreases LM7 and OS482 cells and the cell
numbers decline significantly. The percentage of proliferating cells in all treated samples was
similar to that of control and does not decrease with increase in dose of Riluzole. This sug-
gested that the cells may be lost due to cell death. To test whether Riluzole treatment induces
cell death by apoptosis, we performed the TUNEL assay. Total number of cells were scored by
DAPI staining and apoptotic cells were scored. With increasing doses of Riluzole the number
of apoptotic cells increased in LM7 cells and the total number of cells, as shown by DAPI stain-
ing, decreased (Fig 3A). Moreover, the percentage of apoptotic cells in the samples increased
in a dose dependent manner (Fig 3B and 3C) (p value<0.001 for 50 μM and 100 μM) com-
pared to untreated sample. Similarly, Riluzole increased the number of apoptotic cells in
OS482 cells (Fig 3D). Furthermore, the percentage of apoptotic cells increased in a dose depen-
dent manner (Fig 3E) (p value p value<0.001 for 50 μM and 100 μM) compared to untreated
control.
Riluzole blocks migration of LM7 cells
We further evaluated the effect of Riluzole in LM7 cell migration using a scratch assay as
described in Materials and Methods. Cell migration was determined by measuring the scratch
gap distance in samples treated with DMSO or Riluzole. Representative images of control sam-
ples and Riluzole treated samples used for measuring the gap width and calculating the distance
migrated by cells at 0 hour, 8 hours and 24 hours are shown (Fig 4A). LM7 cells in untreated
sample decreased the gap in 24 hours from 553 to 109 arbitrary units. However, Riluzole treated
LM7 cells decreased the gap in 24 hours 556 to 490 arbitrary units (Fig 4B). The distance mi-
grated by control cells was 117 and 327 arbitrary units at 8 hours and 24 hours respectively.
However, in Riluzole treated samples the cells barely migrated 40 arbitrary units even after 24
hours (Fig 4C). The data from the scratch assay demonstrate that Riluzole prevented migration
of LM7 cells.
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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Blocking specific metabotropic receptors inhibits LM7 cell growth
To identify the specific type of glutamate receptor involved in LM7 cell growth, we employed
specific inhibitors to block mGluR1 and mGluR5 activity in LM7 cells. Cell survival and
Fig 4. Riluzole prevents migration of LM7 cells. Scratch assay was performed to measure migration of
LM7 cells. Cells were either treated with vehicle for control or treated with 100 μM Riluzole, scratched and
images of the gap created were captured at 0 time, 8 and 24 hours using phase contrast inverted scope. A.
Representative images of the scratch in samples at 0 h and 24 hr. B. The gap distance was measured from 3
scratches in each image at 0, 8 and 24 hours. C. The distance travelled by the cells in the images was
measured at 8 and 24 hrs.
doi:10.1371/journal.pone.0171256.g004
Fig 3. Riluzole induces apoptosis in LM7 and OS482 cells. LM7 cells were seeded and treated with Riluzole at various concentrations or
DMSO for control for 72 hours. The cells were fixed and the TUNEL assay was performed. Images were captured and analyzed. A. Blue
bars represent DAPI positive cells and red bars represent TUNEL positive cells. B. Percentage of TUNEL positive cells in each sample was
calculated based in total number of DAPI positive cells for that sample (P value <0.001 = ***). C. Representative images of the TUNEL
assay. D. OS482 were treated with various concentrations of Riluzole or DMSO for control and TUNEL assay was performed as in A. E
Percentage of TUNEL positive cells in each sample was calculated for OS482 cells based in total number of DAPI positive cells for that
sample (P value <0.001 = ***).
doi:10.1371/journal.pone.0171256.g003
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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proliferation were measured in the presence of very potent and specific non-competitive
mGluR1 inhibitor, CPCCOEt (40 μM) or negative allosteric modulator of mGluR5, Fenobam
(300 μM) (Fig 5A and 5B). Treatment with DHPG (50 μM), a group I metabotropic receptor
(mGluR1 and mGluR5) agonist, increased the total number cells as assessed by DAPI staining,
and the increase in Ki-67 positive cells over that of control sample was highly significant (p
value of 0.01) (Fig 5B). Interestingly, CPCCOEt decreased the cell number, which was not sig-
nificant but the decrease in Ki-67 positive cell numbers was significant with a p value of 0.01.
Samples treated with both CPCCOEt plus DHPG showed a slight increase in the number of
DAPI positive and Ki-67 positive cells. However, Fenobam significantly reduced both the
DAPI positive and Ki-67 positive cell numbers with a p value of<0.001 (Fig 5A and 5B).
Importantly, the inhibition by Fenobam was comparable to that of Riluzole. DHPG treatment
did not rescue the inhibition by Fenobam when DHPG was used in combination with Feno-
bam (P value<0.001). Apoptosis was also measured by TUNEL assay (Fig 5C). The only sam-
ple that shows a significant difference in apoptosis compared to the control is the Riluzole plus
DHPG treated sample. However, there was a significant decline in the total number of the cells
(DAPI positive, Fig 5A) for drug treated samples, due to loss of cells by apoptosis, compared to
the untreated sample, therefore we calculated percentage of apoptotic cells from Fig 5A taking
DAPI positive cells as 100% for each sample as shown in Fig 5D. Only Riluzole (p value<0.001)
and Fenobam (p value<0.001) treatment resulted in the highest percentage of apoptotic cells
and DHPG did not rescue the effect of Riluzole when added along with Riluzole (p value<
0.001). These results indicate Riluzole and Fenobam are inducing apoptosis most effectively. We
Fig 5. Blocking metabotropic receptors inhibits LM7 growth. A. Specific inhibitor of mGluR1, CPCCOEt (CCPD) 40 μM or mGluR5
inhibitor, Fenobam 300 μM, were used to measure total number of cell by DAPI staining. B. Proliferation was measured using Ki-67
staining after blocking with specific mGluR inhibitor. C. Apoptosis was performed using TUNEL in LM7 cells in the presence of specific
mGluR1 or mGluR5 inhibitors. D. Percent apoptosis was calculated based on DAPI numbers for samples in Fig 5A. E. LM7 cells express
mGluR5. Whole cell extracts from LM7 cells were analyzed by Western blot using mGluR5 antibodies. P value <0.01 = **, P value <
0.001 = ****.
doi:10.1371/journal.pone.0171256.g005
Riluzole inhibits osteosarcoma proliferation, induces apoptosis, and prevents migration
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further tested the expression of mGluR5 in whole cell extract of LM7 cells by western blot. Whole
cell extract from U87 cells was used as a positive control for mGluR5 expression. We observed
mGlu R5 expression in LM7 cells (Fig 5E), however, we did not detect mGluR1 protein expres-
sion (data not shown). These data indicated that of the Type 1 receptors, mGluR5 is predomi-
nantly expressed in LM7 cells. Specifically, blocking the activation of mGluR5 by Fenobam
significantly reduced total number of cells, proliferating cells, and induced apoptosis, which is
similar to the effect of Riluzole on LM7 cells. These data suggests that mGluR5 plays a key role in
the proliferation of LM7 cells.
Riluzole alters phosphorylation status of downstream signaling
molecules
mGluR1/5 are known to signal through PI3 Kinase which are tethered to the membrane via
Homer to initiate signaling in metabolism, cell survival, proliferation and tumor progression
[36, 37]. To further determine the effect of Riluzole on glutamate induced signaling pathways
we examined the phosphorylation status of signaling proteins such as Akt, which participates
in signaling survival, cell growth, cell proliferation, and migration in normal and cancer cells
[38, 39]. Riluzole treatment induced robust increase in phosphorylation at AKT Threonine
308 at 15 with peak at 30 minutes. Similarly, Riluzole increased phosphorylation at AKT Serine
473 with a peak at 15 and 30 minutes. (Fig 6A). Total Akt was used to obtain relative densities
of the bands at different time points and μ-Tubulin used as a loading control shows equal pro-
tein in all lanes. Increase in phosphorylation at T308 or S473 was highly significant with a p
value of< 0–0001. Akt phosphorylates mTOR, which is involved in cell proliferation and cell
survival. Phosphorylation of P70 S6 Kinase at threonine 389 is a hallmark of mTOR activation
[40]. Therefore, we also examined the phosphorylation status of P70 S6 Kinase after Riluzole
treatment and observed decrease in phosphorylation at 15, 30 minutes, however, at 60 the
phosphorylation was similar to that of the control. The decrease in phosphorylation at 15 and
30 minutes was highly significant with a p value of<0.0001 (Fig 6A). The phsophorylation of
ERK1/2 showed an increase at 30 minutes and decreased at 60 minutes after treatment with
Riluzole which was highly significant with a p value of<0.0001. Riluzole also altered the phso-
phorylation status of JNK1/2. Riluzole decreased the phosphorylation of JNK1/2 at 15 minutes,
30 minutes and 60 minutes after treatment, the difference was highly significant compared to
untreated control with a p value of<0.0001. Total ERK1/2 and total JNK1/2 were used to
obtain the relative densities of the phosphorylated protein at each time point (Fig 6B). Hence,
Riluzole treatment alters phosphorylation status of AKT at T308 and S473, P70 S6 kinase,
ERK1/2 and JNK1/2. Thus Riluzole affects signaling pathways involved in cell survival, cell
growth and proliferation.
Knockdown of mGluR5 leads to inhibition of growth
To further verify that mGluR5 is the key receptor involved in glutamate-dependent proliferation
of LM7 cells, we knocked down the expression of mGluR5 using Lentivirus expressing ShRNA for
mGluR5. The stable cell lines expressing ShRNA for mGluR5 or non-target ShRNA were selected
using puromycin in the culture media. A colony-forming assay was performed as described in
Materials and Methods. Wild type LM7 and non-target ShRNA control show visible colonies after
two weeks incubation. However, mGluR5 KO cells did not show visible colonies (Fig 7A). The
number of colonies in the plates were quantified Fig 7B. Expression of mGluR5 was determined
using western blot of whole cell extracts using anti-mGluR5 antibody (Fig 7C). mGluR5 KO does
not show expression of mGluR5 while WT and control ShRNA samples show mGluR5 expres-
sion. The results provide evidence that mGluR5 plays an important role in signaling glutamate
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dependent proliferation in LM7 cells. The schematic of inhibition of LM7 cell proliferation by
Riluzole or Fenobam is depicted (Fig 8).
Discussion
In the present study we have demonstrated that Riluzole inhibits proliferation, induces apopto-
sis of human osteosarcoma, LM7 and mouse osteosarcoma OS482 cells. Riluzole also prevents
migration in LM7, osteosarcoma cells. Loss of migration in Riluzole treated cells could be
largely due to these cells undergoing apoptosis. We have also shown that blocking mGluR5
receptor activation by allosteric modulator, Fenobam, prevented proliferation and induced
apoptosis. Knock down of mGluR5 resulted in significant decrease in colony forming ability of
the LM7 cells and mimics the effects of Riluzole treatment. We further demonstrate that sig-
naling through mGluR5 via the AKT pathway is altered along with ERK1/2 and JNK1/2
Fig 6. Riluzole alters phosphorylation status of AKT, ERK1/2 and JNK. A. Western blotting was carried
out using antibodies against Phospho AKT T308 or phospho AKT S473 or total AKT or phospho P70S6 Kinase
or total P70S6 kinase. Relative densities of the western blots are shown in the right panel. P value<0.0001 =
*** and NS = not significant. B Antibodies against Phospho ERK1/2, total ERK1/2, Phospho JNK1/2, and total
JNK1/2 were tested. Tubulin was used as a loading control. Relative densities of the western blots are shown
in the right panel. P value<0.0001 = *** and NS = not significant.
doi:10.1371/journal.pone.0171256.g006
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pathway. Thus Riluzole likely prevents the activation of mGluR5 receptor and other plausible
receptors or channels that may be involved in proliferation to exert its effects on osteosarcoma
cells. Riluzole has been employed successfully to target melanoma cells, triple negative breast
cancer cells and has been tested in clinical trial for melanoma [24, 28, 29, 41]. Riluzole is used
for treating Amyotropic Lateral Sclerosis patients for over two decades and has been shown to
reduce glutamate levels in the cerebrospinal fluid and prolong life span [42–44]. Riluzole is an
Fig 7. Knockdown of mGluR5 slows growth of LM7 cells. Colonies stained by Cresyl Violet are shown
from WT, control ShRNA and mGluR5 KO samples. B. The number of colonies in each sample from three
independent experiments. C. Western blot of whole cells extracts from WT, control ShRNA and mGluR5 KO
using anti mGluR5 antibody. μ-Tubulin is used as a loading control.
doi:10.1371/journal.pone.0171256.g007
Fig 8. Schematic of mechanism of action of Riluzole. Glutamate released from LM7 cells binds and
activates mGluR receptor signaling that in turn induces the activation of genes involved in proliferation.
Riluzole treatment inhibits glutamate release thereby preventing the activation of glutamate receptors.
Similarly, blocking of mGluR receptors with Fenobam also prevents mGluR5 activation and signaling thereby
blocking activation of proliferation genes.
doi:10.1371/journal.pone.0171256.g008
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approved drug by FDA, its toxicity is characterized and is well tolerated in patients [45]. We
therefore investigated the use of Riluzole and an anti-cancer agent for osteosarcoma using
LM7 cells.
Glutamate signaling was first demonstrated in osteoblasts and osteoclasts as part of normal
bone signaling [46, 47]. Spontaneous secretion of glutamate by osteosarcoma cells was demon-
strated in MG63 and Saos-2 cells lines. However, osteocyte like MLO-Y4 cells did not release
glutamate [48]. MG63 cells were later shown to express various types of glutamate receptors
using RT-PCR [49]. Although glutamate signaling is important in normal bone growth and
remodeling, a genome wide association study, using 941 osteosarcoma patients samples and
3291 cancer free adults of European ancestry, concluded that mGulR4 loci is affected in osteo-
sarcoma. A later study using osteosarcoma samples from 40 patients and 118 paraffin embedded
osteosarcoma tissues showed that osteosarcoma samples express higher levels of mGluR4 com-
pared to normal bone tissue [50]. The same study also showed higher expression of mGluR1
and mGluR5 in osteosarcoma [50]. In osteoblast-like osteosarcoma cells, MG63 cells dexamtha-
sone induced expression of mGluR5 [51]. Interestingly, a recent study has shown that only 20%
of osteosarcoma screened showed higher mGluR4 expression [52]. Exaggerated glutamate sig-
naling plays an important role in tumorigenicity and malignancy of osteosarcoma.
We have demonstrated that LM7 cells secrete glutamate and blocking glutamate secretion
with Riluzole inhibited their growth. The viability of cells in all samples for glutamate assay
remained high around 98% ensuring that the glutamate released was indeed from live cells and
not from lysed dead cells. Riluzole also decreased Ki-67 positive cells indicative of loss of pro-
liferating cells. Importantly, in bone tumors Ki-67 expression level is correlated with degree of
malignancy and serves well in prognosis [53]. It is conceivable that Riluzole might be targeting
proliferating cells to induce apoptosis. Apoptosis induced by Riluzole suggests the importance
of autocrine signaling of glutamate in LM7 cells. LM7 cells are adapted to exploit glutamate
signaling for their growth and preventing glutamate release results in apoptosis. We have
observed a marginal increase in growth by DHPG, which is most likely due to saturation of
receptors due excessive levels of glutamate. DHPG was unable to rescue inhibition by Riluzole
or Fenobam suggesting that these two drugs showed a strong inhibition of mGluR5 receptor,
which could not be reversed. In contrast, CPCCOEt did show significant inhibition of cell pro-
liferation (p value<0.01), however, CPCCOEt did not induce significant apoptotic death sug-
gesting that inhibition of mGluR1 receptor activity altered proliferation status of the cells but
did not induce apoptosis in the cells. Therefore, mGluR1 may not be playing a major role in
survival of LM7 cells. This was further corroborated by the lack of mGluR1 protein expression.
It is interesting to note that in breast cancer, Riluzole was shown to exert anti-tumorigenic
activity independent of mGluR1 expression [54]. Furthermore, Riluzole induced apoptosis in
prostrate cancer through endoplasmic stress [27].
In the present study we also demonstrated that AKT phosphorylation at T308 and S473 is
altered upon Riluzole treatment. Riluzole treatment also altered p70 S6 kinase phosphorylation
demonstrating that mGluR5 signaling through PI3/AKT/mTOR pathway is affected. It is well
known that mGluR1/5 receptors are linked to and activate the PI3/AKT/mTOR pathway [19,
55]. Our data showed that Riluzole also altered phosphorylation status of ERK1/2. Interest-
ingly, mGluR5 has been shown to activate ERK1/2 signaling via G-alpha q-protein but not
through phospholipase C beta1 [56]. We did not observe any changes in PLCμ phosphoryla-
tion status upon Riluzole treatment (data not shown). Furthermore, we show Riluzole treat-
ment results in altered phosphorylation of JNK1/2. Signaling through G-alpha q-protein
coupled mGluR5 receptors results in transactivation of EGF receptor, which in turn activates
JNK phosphorylation [57, 58]. Although mGluR5 activation can lead to changes in more than
one signaling pathway, it is conceivable that Riluzole could be blocking other glutamate
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receptors that may be present in LM7 cells. We have tested for the expression of AMPA recep-
tors subunits GluR1, GluR2 and NMDA receptor subunits NR1, NR2A, NR2B and did not
detect their expression in LM7 cells (data not shown). However, we have not tested for the
expression of mGluR4 in LM7 cells, which is known to activate cAMP pathway. Knock down
of mGluR5 resulted in significant decrease in colony formation ability of mGluR5 KO LM7
cells. The mGluR5 knock down data along with inhibitor data suggests mGluR5 is indeed a
key player in signaling growth in LM7 cells.
In conclusion, we have demonstrated that treatment with Riluzole or blocking mGluR5
receptors with Fenobam decreases cell proliferation and induces apoptosis in LM7 cells suggest-
ing that mGluR5 receptors might play a key role in the proliferation of LM7 cells. Moreover,
knock down of mGluR5 receptors significantly slowed proliferation of LM7 cells. Riluzole dis-
rupts autocrine signaling by depriving the cells of extracellular glutamate preventing activation
of mGluR5. Riluzole blocks glutamate secretion, however, Fenobam prevents activation of
mGluR5 receptor both Riluzole and Fenobam prevent proliferation of LM7 cells as depicted in
Fig 8. Notably, Riluzole also blocked proliferation and induced apoptosis in OS482 cells. There-
fore, treatment with Riluzole may be effective in inhibiting growth and inducing apoptosis in
osteosarcoma cells that utilize glutamate for growth signaling. Our data provides evidence for
the therapeutic potential of Riluzole in osteosarcoma.
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